Imprecise Medicine? Measurement Error and Personalized Treatments

Michael Wallace, University of Waterloo

Slides available at: mpwallace.github.io

Glaucoma: group of eye diseases associated with elevated intraocular pressure (IOP).

IOP can be measured in various ways.



Elevated IOP can cause vision loss, which can be measured through visual field tests.

Treatment options attempt to lower IOP (and by extension preserve visual field), they include:

- Lifestyle changes.
- Eye drops (numerous options).
- Surgery.

Treatment decisions are made based on various factors:

- Current and past IOP.
- Current and past treatments.
- Concerns over side effects.
- Broader risk factors.
- Other characteristics (such as age).

Treatment decisions are made based on various factors:

- Current and past IOP.
- Current and past treatments.
- Concerns over side effects.
- Broader risk factors.
- Other characteristics (such as age).

<u>Precision Medicine</u>: tailoring treatment decisions to patient-level characteristics.

Dynamic treatment regimes (DTRs) 'formalize' personalized treatment:



Dynamic treatment regimes (DTRs) 'formalize' personalized treatment:



 "Patient is currently taking Azarga eye drops. If current IOP is 15 or higher, add Alphagan eye drops, otherwise continue with only Azarga." Dynamic treatment regimes (DTRs) 'formalize' personalized treatment:



- "Patient is currently taking Azarga eye drops. If current IOP is 15 or higher, add Alphagan eye drops, otherwise continue with only Azarga."
- How do we choose the best DTR?
 Should our IOP cut-off be 13, 15, 20?
- What makes this difficult?

We typically work with data from observational studies.

	Observed	Drop	VFP at
Patient	IOP	added?	3 months
1	16	No	73
2	20	Yes	55
3	21	Yes	50
4	16	Yes	61
5	15	No	42

VFP = Visual Field Percentage

We typically work with data from observational studies.

	Observed	Drop	VFP at
Patient	IOP	added?	3 months
	X	A	Y
1	16	No	73
2	20	Yes	55
3	21	Yes	50
4	16	Yes	61
5	15	No	42

VFP = Visual Field Percentage

Notation



DTR: treatment A^{opt} that optimizes $E[Y|X, A^{opt}]$



DTR: treatment sequence A_1^{opt}, A_2^{opt}





Single Stage Analysis



	Observed	Drop	VFP at
Patient	IOP	added?	3 months
	X	A	Y
1	16	No	73
2	20	Yes	55
3	21	Yes	50
4	16	Yes	61
5	15	No	42

Lots of methods available:



Lots of methods available:



If only one treatment decision:

$$\underbrace{E[Y|X,A]}$$

Expected outcome (to be maximized)

$$A \in \{0,1\}$$

If only one treatment decision:



$$A \in \{0,1\}$$

We might propose the following model

 $E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 \mathsf{IOP} + A(\psi_0 + \psi_1 \mathsf{IOP})$ " $A^{opt} = 1 \text{ if } \psi_0 + \psi_1 \mathsf{IOP} > 0$ "

If only one treatment decision:

 $\underbrace{E[Y|X,A]}_{\text{Expected outcome}}$

(to be maximized)

 $A \in \{0,1\}$

We might propose the following model

 $E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 \mathsf{IOP} + A(\psi_0 + \psi_1 \mathsf{IOP})$ " $A^{opt} = 1 \text{ if } \psi_0 + \psi_1 \mathsf{IOP} > 0$ "

More generally, split outcome into two components:



• Simplifies focus: find A^{opt} that maximizes $\gamma(X, A; \psi)$.

• Suppose the true outcome model is: $E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 IOP + \beta_2 IOP^2 + A(\psi_0 + \psi_1 IOP)$ • Suppose the true outcome model is: $E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 IOP + \beta_2 IOP^2 + A(\psi_0 + \psi_1 IOP)$

But we propose:

 $E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 \mathsf{IOP} + A(\psi_0 + \psi_1 \mathsf{IOP})$

Dynamic WOLS (dWOLS)

$E[Y|X, A; \beta, \psi] = G(X; \beta) + \gamma(X, A; \psi)$

- Three models to specify:
 - 1. Blip model: $\gamma(X, A; \psi)$.
 - 2. Treatment-free model: $G(X; \beta)$.
 - 3. Treatment model: $P(A = 1|X; \alpha)$.

Dynamic WOLS (dWOLS)

$E[Y|X, A; \beta, \psi] = G(X; \beta) + \gamma(X, A; \psi)$

Three models to specify:

- 1. Blip model: $\gamma(X, A; \psi)$.
- 2. Treatment-free model: $G(X; \beta)$.
- 3. Treatment model: $P(A = 1|X; \alpha)$.
- Estimate ψ via WOLS of Y on covariates in blip and treatment-free models, with weights w = |A − P(A = 1|X; â)|.

Suppose the true outcome model is:

 $E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 \mathsf{IOP} + \beta_2 \mathsf{IOP}^2 + A(\psi_0 + \psi_1 \mathsf{IOP})$

 $E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 \mathsf{IOP} + \beta_2 \mathsf{IOP}^2 + A(\psi_0 + \psi_1 \mathsf{IOP})$

But we propose:

 $E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 \mathsf{IOP} + A(\psi_0 + \psi_1 \mathsf{IOP})$

 $E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 \mathsf{IOP} + \beta_2 \mathsf{IOP}^2 + A(\psi_0 + \psi_1 \mathsf{IOP})$

But we propose:

 $E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 \mathsf{IOP} + A(\psi_0 + \psi_1 \mathsf{IOP})$

• A weighted regression with weights $w = |A - P(A = 1|X; \hat{\alpha})|$ will still yield consistent estimators of ψ_0, ψ_1 .

 $E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 \mathsf{IOP} + \beta_2 \mathsf{IOP}^2 + A(\psi_0 + \psi_1 \mathsf{IOP})$

But we propose:

 $E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 \mathsf{IOP} + A(\psi_0 + \psi_1 \mathsf{IOP})$

- A weighted regression with weights $w = |A P(A = 1|X; \hat{\alpha})|$ will still yield consistent estimators of ψ_0, ψ_1 .
- The estimators are "doubly robust": consistent if at least one of the treatment-free or treatment components is correctly specified.
- The blip must always be correct.



More formally, write \widetilde{Y}_j for the stage j 'pseudo-outcome'.

 \widetilde{Y}_j is the expected outcome assuming optimal treatment from stage j+1 onwards.

Pseudo-outcome = **observed outcome** + estimated 'loss' of receiving non-optimal treatments

More formally, write \widetilde{Y}_j for the stage j 'pseudo-outcome'.

 \widetilde{Y}_j is the expected outcome assuming optimal treatment from stage j+1 onwards.

Pseudo-outcome = observed outcome + estimated 'loss' of receiving non-optimal treatments

$$\widetilde{Y}_{j} = Y + \sum_{k=j+1}^{J} [\gamma_{k}(X_{k}, A_{k}^{opt}; \hat{\psi}_{k}) - \gamma_{k}(X_{k}, A_{k}; \hat{\psi}_{k})]$$

We plug \widetilde{Y}_j into our dWOLS procedure and proceed similarly.

Measurement error



History

Target measurement: 'average' IOP.

Observed measurement: 1-3 in-clinic readings within < 5 minutes.

Some patients have access to more regular at-home tonometry.



Treatment

Target measurement: adherence with prescribed dosing regimen.

Observed measurement: prescribed treatment or patient-reported adherence.

Full adherence with therapies reported in 10% of patients.



Outcome

Target measurement: % of remaining vision.

Observed measurement: visual field test.



Measurement error



Measurement error



Measurement Error



Measurement Error



Estimation: suppose the true outcome model is:

$$E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 X + \beta_2 X^2 + A(\psi_0 + \psi_1 X)$$

But we only observe

$$X^* = X + U$$
 $U \sim N(\mu_u, \sigma_u^2)$

Regression Calibration

Simple correction method: Regression Calibration.

Principle:

- 1. Use additional data to estimate $E[X|X^*, A] = X_{rc}$.
- 2. Replace X with X_{rc} and carry out a standard analysis.
- 3. Adjust the resulting standard errors to account for the estimation in step 1.

	First IOP	Second IOP
Patient	measurement	measurement
1	16	15
2	20	16
3	21	17
4	16	16
5	15	18

 $E[Y|\cdot] = \beta_0 + \beta_1 X + \beta_2 X^2 + A(\psi_0 + \psi_1 X)$



 $E[Y|\cdot] = \beta_0 + \beta_1 X + \overline{\beta_2 X^2 + A(\psi_0 + \psi_1 X)}$

• If we have RC estimates X_{rc} then we could fit $E[Y|\cdot] = \beta_0 + \beta_1 X_{rc} + \beta_2 X_{rc}^2 + A(\psi_0 + \psi_1 X_{rc})$



 $E[Y|\cdot] = \beta_0 + \beta_1 X + \beta_2 X^2 + A(\psi_0 + \psi_1 X)$

• If we have RC estimates X_{rc} then we could fit

$$E[Y|\cdot] = \beta_0 + \beta_1 X_{rc} + \beta_2 X_{rc}^2 + A(\psi_0 + \psi_1 X_{rc})$$

But we might mis-specify the model as

 $E[Y|\cdot] = \overline{\beta_0 + \beta_1 X_{rc} + A(\psi_0 + \psi_1 X_{rc})}$

where A depends on X^* .



 $E[Y|\cdot] = \beta_0 + \beta_1 X + \overline{\beta_2 X^2} + A(\psi_0 + \psi_1 X)$

• If we have RC estimates X_{rc} then we could fit

$$E[Y|\cdot] = \beta_0 + \beta_1 X_{rc} + \beta_2 X_{rc}^2 + A(\psi_0 + \psi_1 X_{rc})$$

But we might mis-specify the model as

 $E[Y|\cdot] = \beta_0 + \beta_1 X_{rc} + A(\psi_0 + \psi_1 X_{rc})$

where A depends on X^* .

• Solution: dWOLS using $P(A = 1|X_{rc})$ estimates.





Measurement error



For binary A, misclassification can be characterized by the positive and negative predictive values:

$$PPV = P(A = 1 | A^* = 1)$$
 $NPV = P(A = 0 | A^* = 0)$

Measurement error



Suppose the true outcome model is:

$$E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 X + \beta_2 X^2 + A(\psi_0 + \psi_1 X)$$

but we only observe A^* .

Key question: do the misclassification probabilities depend on X?

$$E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 X + \beta_2 X^2 + A(\psi_0 + \psi_1 X)$$

If misclassification does <u>not</u> depend on X, then our estimates of ψ_0, ψ_1 will be biased:

$$\psi_0^* = (PPV + NPV - 1)\psi_0 \qquad \psi_1^* = (PPV + NPV - 1)\psi_1$$

$$E[Y|X,A;\beta,\psi] = \beta_0 + \beta_1 X + \beta_2 X^2 + A(\psi_0 + \psi_1 X)$$

If misclassification does <u>not</u> depend on X, then our estimates of ψ_0, ψ_1 will be biased:

$$\psi_0^* = (PPV + NPV - 1)\psi_0 \qquad \psi_1^* = (PPV + NPV - 1)\psi_1$$

However: our treatment rule is of the form

$$A^{opt} = 1$$
 if $\psi_0 + \psi_1 X > 0$

which is unaffected if ψ_0, ψ_1 are biased by the same factor.

If misclassification depends on X, then corrective action is required.

Upcoming work modifies G-estimation to account for treatment misclassification.

Further questions exist related to intention to treat analyses, and implications of (non-) adherence for identifying optimal treatment rules.

Measurement error



Measurement error



Suppose the true outcome model is:

$$E[Y|X, A; \beta, \psi] = \beta_0 + \beta_1 X + \beta_2 X^2 + A(\psi_0 + \psi_1 X)$$

but we only observe

$$Y^* = Y + U$$
 $U \sim N(\mu_u, \sigma_u^2)$

$$\begin{split} E[Y|X, A; \beta, \psi] &= \beta_0 + \beta_1 X + \beta_2 X^2 + A(\psi_0 + \psi_1 X) \\ Y^* &= Y + U \qquad U \sim \mathcal{N}(\mu_u, \sigma_u^2) \end{split}$$

• Unbiased error: parameter estimates also unbiased.

$$\begin{split} E[Y|X, A; \beta, \psi] &= \beta_0 + \beta_1 X + \beta_2 X^2 + A(\psi_0 + \psi_1 X) \\ Y^* &= Y + U \qquad U \sim \mathcal{N}(\mu_u, \sigma_u^2) \end{split}$$

- Unbiased error: parameter estimates also unbiased.
- Biased error, independent of A: ψ estimators still consistent.

$$\begin{split} E[Y|X, A; \beta, \psi] &= \beta_0 + \beta_1 X + \beta_2 X^2 + A(\psi_0 + \psi_1 X) \\ Y^* &= Y + U \qquad U \sim N(\mu_u, \sigma_u^2) \end{split}$$

- Unbiased error: parameter estimates also unbiased.
- Biased error, independent of A: ψ estimators still consistent.
- Biased error, not independent of A: ψ estimators no longer reliable.

Measurement Error and Pseudo-outcomes



Recall the multi-stage case requires the computation of pseudo-outcomes:

$$\tilde{Y}_j = Y + \sum_{k=j+1}^{J} [\gamma_k(X_k, A_k^{opt}; \hat{\psi}_k) - \gamma_k(X_k, A_k; \hat{\psi}_k)].$$

Errors in X, A, or Y create additional problems.

"If 3-month average IOP \geq 15 add secondary drop, otherwise, maintain current treatment regime."

"If 3-month average IOP \geq 15 add secondary drop, otherwise, maintain current treatment regime."

I go to the clinic and my IOP measurement is 16. Then what?

"If 3-month average IOP \geq 15 add secondary drop, otherwise, maintain current treatment regime."

I go to the clinic and my IOP measurement is 16. Then what?

What is $P(X < 15 | X^* = 16)$?

Data availability will vary by study and by variable:

Scenario	Analysis	Application
1: "We never observe the truth."	X*	<i>X</i> *

"Isn't this just a prediction problem?"

What if error-free data are possible, but expensive?

Scenario	Analysis	Application
1: "We never observe the truth."	<i>X</i> *	<i>X</i> *
2: "Past data are error-prone, but	<i>X</i> *	X
future data may not be."		
3: "Past data are not error-prone,	X	X*
but future data may be."		

"Isn't this just a prediction problem?"

Only Scenario 4 is well-studied.

Scenario	Analysis	Application
1: "We never observe the truth."	<i>X</i> *	<i>X</i> *
2: "Past data are error-prone, but	X*	X
future data may not be."		
3: "Past data are not error-prone,	X	<i>X</i> *
but future data may be."		
4: "We always observe the truth."	X	X

"If 3-month average IOP \geq 15 add secondary drop, otherwise, maintain current treatment regime."

I go to the clinic and my IOP measurement is 16. Then what?

Future Treatment

We can explore such probabilities through computation/simulation:



https://shiny.math.uwaterloo.ca/sas/mwallace/probmistreat/

- DTRs an important tool in precision medicine.
- Measurement error an important consideration in patient history, treatment, outcome, and future decision making.
- There are some special cases where errors have limited impact, or may be corrected for with standard theory.
- But: many more cases to explore.



Acknowledgments



Dylan Spicker dylan.spicker@uwaterloo.ca



- dWOLS: M. P. Wallace and E. E. M. Moodie (2015). Doubly-robust dynamic treatment regimen estimation via weighted least squares. Biometrics 71(3) 636-644.
- Precision Medicine and Measurement Error in Tailoring Variates: D. Spicker and M. P. Wallace (2020). Measurement error and precision medicine: error-prone tailoring covariates in dynamic treatment regimes. Statistics in Medicine **39(26)** https://doi.org/10.1002/sim.8690
- Precision Medicine and Measurement Error More Broadly: M. P. Wallace. Measurement error and precision medicine. In Cai T., Chakraborty B., Laber E., Moodie E. and van der Laan M. (Eds), Handbook of Statistical Methods for Precision Medicine. Chapman & Hall/CRC Handbooks of Modern Statistical Methods. Expected publication 2022.



🖂 michael.wallace@uwaterloo.ca



mpwallace.github.io